Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NBP 615

Drug Profile

NBP 615

Alternative Names: NBP-615; SK-NBP615

Latest Information Update: 23 Feb 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SK Chemicals
  • Developer SK Bioscience
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; Papillomavirus vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Cervical cancer

Most Recent Events

  • 23 Feb 2022 No development reported - Phase-I/II for Cervical cancer (In adolescents, In children, Prevention, In adults) in South Korea (IM) (NCT04453241)
  • 07 Jul 2020 NBP 615 is still in phase I/II trials for Cervical cancer (Prevention, In adolescents, In adults, In children) in South Korea (IM) (NCT04453241)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top